BeyondSpring Inc Dossier
Qualitative Analysis
Business overview
BeyondSpring Inc. (NASDAQ: BYSI) is a clinical-stage global biopharmaceutical company focused on developing transformative, first-in-class cancer therapies to improve clinical outcomes for patients with high unmet medical needs. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA) and first-in-class GEF-H1 agonist. Plinabulin operates via a multi-functional mechanism of action that triggers dendritic cell maturation, modulates the tumor microenvironment, and prevents chemotherapy-induced neutropenia (CIN). BeyondSpring also holds a significant equity interest in SEED Therapeutics, a subsidiary focused on targeted protein degradation and molecular glue discovery.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Executing the 442-patient confirmatory Phase 3 trial of Plinabulin plus docetaxel in non-squamous EGFR wild-type NSCLC patients who progressed on PD-1/PD-L1 inhibitor-containing therapies [1.1.1].
Expected impact: Prospective validation of DUBLIN-3 results to secure global regulatory approvals, particularly with the US FDA.
Developing clinical and partnership frameworks for Plinabulin as a backbone combination agent in Antibody-Drug Conjugate (ADC) regimens, leveraging its GEF-H1 agonist mechanism.
Expected impact: Broadening Plinabulin's long-term clinical utility and commercial reach across the oncology treatment landscape.
Leading strategic engagement with Chinese and Japanese pharmaceutical companies, as well as Asia-based institutional investors active in oncology.
Expected impact: Strengthening the company's financial position, securing development partners, and enhancing capital markets engagement.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Evaluating pembrolizumab in combination with Plinabulin and docetaxel in the Phase 1/2 Study 303 for second-line NSCLC.
Terms: Merck provides clinical trial support and pembrolizumab supply.
BeyondSpring entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED to fund late-stage Plinabulin development, while maintaining a minority equity stake and research collaboration.
Terms: Gross proceeds of approximately $35.4 million to be received in tranches.